Cost analysis of once-daily ISMN versus twice-daily ISMN or transdermal patch for nitrate prophylaxis

R. E. Brown, M. J. Kendall, Michael Halpern

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Objective: To compare the costs and outcomes of treating exercise-induced angina with once- or twice-daily isosorbide mononitrate (ISMN) or transdermal patch. Method: A decision-analytic model was designed based on published literature showing compliance and increasing symptoms and estimates from physicians on treatment patterns and worsening symptoms. Results: Data show that patients are more compliant with once-daily ISMN (Imdur®, Astra Hassle, Molndal, Sweden) and patch regimens than with twice-daily dose. Based upon the assumption that more compliant patients are better controlled, the model found that fewer medical care resources were consumed by patients treated with the once-daily and the patch regimens. The unit cost of the twice-daily ISMN regimen is 40% of the unit cost of the once-daily. Annual costs of treating an exercise-induced angina patient are £248 for Imdur® compared to £250 for the twice-daily ISMN and £299 for the transdermal patch. Conclusion: Unit prices alone are not good indicators for estimating medical management costs.

Original languageEnglish (US)
Pages (from-to)67-76
Number of pages10
JournalJournal of Clinical Pharmacy and Therapeutics
Volume22
Issue number1
StatePublished - 1997
Externally publishedYes

Fingerprint

isosorbide-5-mononitrate
Transdermal Patch
Nitrates
Costs and Cost Analysis
Exercise
Sweden
Compliance
Physicians

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Cost analysis of once-daily ISMN versus twice-daily ISMN or transdermal patch for nitrate prophylaxis. / Brown, R. E.; Kendall, M. J.; Halpern, Michael.

In: Journal of Clinical Pharmacy and Therapeutics, Vol. 22, No. 1, 1997, p. 67-76.

Research output: Contribution to journalArticle

@article{6fd41133f93141f8b840502236841555,
title = "Cost analysis of once-daily ISMN versus twice-daily ISMN or transdermal patch for nitrate prophylaxis",
abstract = "Objective: To compare the costs and outcomes of treating exercise-induced angina with once- or twice-daily isosorbide mononitrate (ISMN) or transdermal patch. Method: A decision-analytic model was designed based on published literature showing compliance and increasing symptoms and estimates from physicians on treatment patterns and worsening symptoms. Results: Data show that patients are more compliant with once-daily ISMN (Imdur{\circledR}, Astra Hassle, Molndal, Sweden) and patch regimens than with twice-daily dose. Based upon the assumption that more compliant patients are better controlled, the model found that fewer medical care resources were consumed by patients treated with the once-daily and the patch regimens. The unit cost of the twice-daily ISMN regimen is 40{\%} of the unit cost of the once-daily. Annual costs of treating an exercise-induced angina patient are £248 for Imdur{\circledR} compared to £250 for the twice-daily ISMN and £299 for the transdermal patch. Conclusion: Unit prices alone are not good indicators for estimating medical management costs.",
author = "Brown, {R. E.} and Kendall, {M. J.} and Michael Halpern",
year = "1997",
language = "English (US)",
volume = "22",
pages = "67--76",
journal = "Journal of Clinical Pharmacy and Therapeutics",
issn = "0269-4727",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Cost analysis of once-daily ISMN versus twice-daily ISMN or transdermal patch for nitrate prophylaxis

AU - Brown, R. E.

AU - Kendall, M. J.

AU - Halpern, Michael

PY - 1997

Y1 - 1997

N2 - Objective: To compare the costs and outcomes of treating exercise-induced angina with once- or twice-daily isosorbide mononitrate (ISMN) or transdermal patch. Method: A decision-analytic model was designed based on published literature showing compliance and increasing symptoms and estimates from physicians on treatment patterns and worsening symptoms. Results: Data show that patients are more compliant with once-daily ISMN (Imdur®, Astra Hassle, Molndal, Sweden) and patch regimens than with twice-daily dose. Based upon the assumption that more compliant patients are better controlled, the model found that fewer medical care resources were consumed by patients treated with the once-daily and the patch regimens. The unit cost of the twice-daily ISMN regimen is 40% of the unit cost of the once-daily. Annual costs of treating an exercise-induced angina patient are £248 for Imdur® compared to £250 for the twice-daily ISMN and £299 for the transdermal patch. Conclusion: Unit prices alone are not good indicators for estimating medical management costs.

AB - Objective: To compare the costs and outcomes of treating exercise-induced angina with once- or twice-daily isosorbide mononitrate (ISMN) or transdermal patch. Method: A decision-analytic model was designed based on published literature showing compliance and increasing symptoms and estimates from physicians on treatment patterns and worsening symptoms. Results: Data show that patients are more compliant with once-daily ISMN (Imdur®, Astra Hassle, Molndal, Sweden) and patch regimens than with twice-daily dose. Based upon the assumption that more compliant patients are better controlled, the model found that fewer medical care resources were consumed by patients treated with the once-daily and the patch regimens. The unit cost of the twice-daily ISMN regimen is 40% of the unit cost of the once-daily. Annual costs of treating an exercise-induced angina patient are £248 for Imdur® compared to £250 for the twice-daily ISMN and £299 for the transdermal patch. Conclusion: Unit prices alone are not good indicators for estimating medical management costs.

UR - http://www.scopus.com/inward/record.url?scp=0030853899&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030853899&partnerID=8YFLogxK

M3 - Article

C2 - 9292406

AN - SCOPUS:0030853899

VL - 22

SP - 67

EP - 76

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 1

ER -